Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Polaryx Therapeutics, Inc.PLYX · Entity 6769 | Director · Chief Executive Officer · 10% owner | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Polaryx Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
Jointly reported with Mstone Partners Healthcare Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Mstone Partners Healthcare Limited | 24,233,249 |
Reported balance
After 2026-05-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-05-27 · Purchase · Acquired 88,453 · Balance 24,233,249 F1: As disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on May 28, 2026, MStone Partners Healthcare Limited ("Mstone") purchased 88,453 shares of common stock in a private placement transaction, for gross proceeds to the Issuer of $360,000. F2: Alex Keun Mo Yang is the founder and Chief Executive Officer of Mstone. Mr. Yang disclaims beneficial ownership over any of the reported securities, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on May 28, 2026, MStone Partners Healthcare Limited ("Mstone") purchased 88,453 shares of common stock in a private placement transaction, for gross proceeds to the Issuer of $360,000.
F2: Alex Keun Mo Yang is the founder and Chief Executive Officer of Mstone. Mr. Yang disclaims beneficial ownership over any of the reported securities, except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 00:00 UTC | Polaryx Therapeutics, Inc. PLYX · Entity 6769 | PurchaseCommon Stock | 88,453 | $4.07 | $360,003.71 |
DisclosureSEC source: 0001213900-26-062322 · ownership.xml · nonDerivative · entry 1 Yang Alex Keun Mo · CIK 0002103399 · Director · Chief Executive Officer · 10% owner Mstone Partners Healthcare Ltd · CIK 0002104809 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Mstone Partners Healthcare Limited Disclosed balance after: 24,233,249 F1 · shares: As disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on May 28, 2026, MStone Partners Healthcare Limited ("Mstone") purchased 88,453 shares of common stock in a private placement transaction, for gross proceeds to the Issuer of $360,000. F2 · ownership.nature: Alex Keun Mo Yang is the founder and Chief Executive Officer of Mstone. Mr. Yang disclaims beneficial ownership over any of the reported securities, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.